Fig. 2

CD36 inhibition by siRNA attenuates VM by melanoma cells in vitro. (A, E) Representative images of C32 and SK-Mel-28 human melanoma cells undergoing VM. For each cell line, the left image depicts VM with low magnification (scale bar = 500 μm) and the right image is a zoomed in view of the same well using higher magnification (scale bar = 100 μm). (B, F) Left panels, flow cytometric histograms of CD36 expression on C32 and SK-Mel-28 cells with isotype control (dotted line), CD36 (solid black line), and siCD36 knockdown cells (A, blue line; B, red line and C, green line). Right panels, bar graphs of flow data quantified from experimental repeats, siCD36 (constructs A-C) normalized to scrambled siRNA (siSCR) controls. Data are expressed as mean ± SEM from n = 3 experiments.***p < 0.001 vs siSCR control, one-way ANOVA. (C, G) Cell viability without and with CD36 knockdown. Data are expressed as mean ± SEM from n = 3 experiments. (D, H) Top panels are representative images of C32 and SK-Mel-28 melanoma cells undergoing VM without or with siCD36 knockdown. For each cell line, the left image depicts VM with low magnification (scale bar = 500 μm) and the right image is a zoomed in view of the same well using higher magnification (scale bar = 100 μm). Lower panels illustrate the VM formation following CD36 knockdown for constructs RNAi A-C. (scale bar = 100 μm) (E, I) Quantitation of VM formation by the cancer cells, normalized to si-SCR control within each experiment. Data are expressed as mean ± SEM from n = 3 experiments. ***p < 0.001 vs si-SCR control, one-way ANOVA